PICO | Description |
---|---|
Population | Patients with type 2 diabetes and chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) of 50-75 ml/min/1.73m² with urinary albumin-to-creatinine ratio >300 to <5000 or eGFR of 25 to <50 ml/min/1.73m² with urinary albumin-to-creatinine ratio >100 to <5000. |
Intervention | Weekly subcutaneous injection of semaglutide at a dose of 1.0 mg, with a follow-up over a median of 3.4 years. |
Comparison | Placebo administered weekly with the same follow-up duration. |
Outcome | Semaglutide reduced the risk of a primary outcome event (major kidney events and death from kidney-related or cardiovascular causes) by 24% compared to placebo. Participants in the semaglutide group also experienced a slower annual decline in eGFR by 1.16 ml/min/1.73m² (p<0.001), a 20% lower risk of death from any cause, and an 18% lower risk of major cardiovascular events. Fewer serious adverse events were reported compared to the placebo group (49.6% vs. 53.8%). |
Source: Perkovic, Vlado, et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.” New England Journal of Medicine, July 2024, Read article here.